Company intelligence / Profile preview

Nuvaila

Ireland

Ownership: Private
Development stage: Other

Overview

Nuvaila is the exclusive US distributor of Amgen's Wezlana, the first interchangeable Stelara (ustekinumab) biosimilar, commercially available since Jan 1, 2025; also distributes biosimilars of adalimumab, with $0 copay for some plans and options for both high-WAC and low-WAC pricing

Therapeutic areas: GastroenterologyDermatologyRheumatology
Modalities: BiologicMonoclonal antibody (for Wezlana/ustekinumab biosimilar)Small molecule (for generics, if applicable)
Industry: Non-Academic Healthcare

Partnerships

Amgen (Wezlana biosimilar manufacturing/distribution)deals with biosimilar manufacturers for portfolio

Beyond the preview

Go deeper on Nuvaila.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvaila.

Explore the full profile